Adheris Health Names John Murray as Director, Reports No Initial Securities or Contract Interests

John Murray Joins Adheris Health Board from 1 July 2026

Adheris Health Limited has officially informed the market of John Murray’s appointment as a director, effective 1 July 2026. This notification was made via an Appendix 3X, the standard form required by the ASX Listing Rules for new directors joining a listed company’s board.

The filing establishes the starting point for tracking Murray’s holdings and interests in Adheris Health. Under the ASX continuous disclosure regime, any acquisitions, disposals, or changes in his interests must be promptly reported through an Appendix 3Y, or Change of Director's Interest Notice. As at the appointment date, Murray declared no shares, options, convertible securities, or contractual interests.

Murray Holds No Securities at Appointment

Part 1 of the Initial Director's Interest Notice, which details securities held directly by the director, records a nil holding for John Murray. This means that on 1 July 2026, he did not directly own any shares, options, performance rights, or other securities in Adheris Health Limited.

This is common for newly appointed directors, especially those appointed externally rather than from existing major shareholders. Directors often accumulate securities over time through market purchases or participation in equity incentive plans, which would require subsequent disclosure.

No Beneficial or Indirect Securities Interests Reported

Part 2 of the notice covers securities where the director has a relevant interest but is not the registered holder, such as holdings via family trusts or corporate entities. For Murray, this section also records nil, indicating no indirect or beneficial interests at appointment.

The absence of indirect holdings confirms Murray currently holds no financial stake in Adheris Health through associated entities. Investors tracking director alignment with shareholder interests will watch for any future personal share acquisitions.

No Contractual Interests Declared by Incoming Director

Part 3 of the Appendix 3X addresses any contracts the director has with the company, including service agreements, consulting contracts, or loan arrangements. Murray’s filing shows nil across all fields, indicating no such contracts existed at appointment.

The company did not disclose any remuneration details, service agreements, or terms related to Murray’s directorship in this filing. Such information may be provided later through separate announcements or in the company’s next Annual Report or remuneration report.

Regulatory Requirements for Appendix 3X Filing

The Appendix 3X lodgement is mandatory under ASX Listing Rule 3.19A.1, requiring listed companies to notify the exchange immediately upon appointing a new director. It is also lodged under section 205G of the Corporations Act 2001, which mandates disclosure of directors’ shareholdings and contractual interests.

Once submitted, this information becomes public and forms part of the ASX’s commitment to market transparency. The Appendix 3X provides an auditable baseline of each director’s financial interests from the moment they join the board.

Implications of the Clean-Slate Filing for Future Disclosures

Since Murray’s Initial Director’s Interest Notice reports nil holdings and interests, any future transactions involving Adheris Health securities or contracts will represent changes from this baseline. The ASX requires directors to notify the company of such changes, which must be lodged with the exchange within five business days via an Appendix 3Y.

Investors who view director trading activity as a signal of management confidence will monitor for any Appendix 3Y filings following Murray’s start date. Any on-market share purchases or participation in equity incentive schemes will be promptly disclosed, updating the market on his alignment with shareholders.

About Adheris Health Limited and Its ASX Listing

Adheris Health Limited is listed on the ASX under ticker AHE with ABN 17 145 327 617. While the company’s name and branding suggest a focus in the health sector, no further operational or strategic details were provided in this update. Investors seeking comprehensive information should consult the company’s latest annual report, investor presentations, and continuous disclosure documents lodged with the ASX.

Board appointments are important governance events that can influence a company’s strategic direction, capital allocation, and governance culture. The market will be interested in further context from Adheris Health regarding Murray’s appointment, including his professional background and expertise, none of which was included in the Appendix 3X filing.

Investor Considerations on Board Changes at Adheris Health

New director appointments can impact investor sentiment, especially if the appointee brings specialist skills or signals strategic shifts. However, based on this announcement alone, no additional information about Murray’s qualifications or intended role has been disclosed.

The immediate effect on the share price was not evident from available data. Investors should watch for further company announcements, media releases, or governance updates that provide more insight into Murray’s role and the board’s composition.

Upcoming Disclosure Events Following Murray’s Appointment

With John Murray joining the board on 1 July 2026, investors should anticipate disclosures of any changes in his securities holdings or contractual arrangements via Appendix 3Y filings. Additionally, any broader company updates explaining the rationale for the board change or providing operational and financial updates may follow.

The next key milestones will be any subsequent filings or corporate communications that elaborate on the initial notice and provide further detail on Murray’s appointment and Adheris Health’s governance.